Ocugen, Inc.
At Ocugen, we are focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, we are advancing vaccine research in the fight against COVID-19, and our work in cell therapy is aimed at orthopedic disease for which no effective treatment options currently exist.
NEWS
There’s a new collaboration in the Parkinson’s disease development space, Cardiff Oncology kicks off a mid-phase study in colorectal cancer and Ocugen published a new review of COVAXIN.
Homology Medicines and MiMedx both posted new CEOs. Other C-suite positions, including CFOs and CMOs were also filled this week.
The week began with positive updates in the vaccine development space against various infectious diseases from Emergent, Merck, Affinivax and Ocugen.
Lifting the clinical hold will allow Ocugen to continue to assess the vaccine in its ongoing study and potentially support its efforts to achieve EUA or full approval.
A roundup of last week’s top clinical trial updates and news.
Ocugen has amended its co-development, supply and commercialization deal with Bharat to include Mexico and now holds the rights for the Covaxin vaccine for all of North America.
It was a particularly busy week for clinical trial announcements. Let’s take a look.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
The FDA lifts its clinical hold on Ocugen’s COVID-19 vaccine, and Ocugen announces a clinical trial for the treatment of inherited retinal diseases.
JOBS
IN THE PRESS